News & Events

News

Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who, like us, believe noninvasive brain stimulation harnesses the brain's own healing power—neuroplasticity. Nexstim is helping patients—and their families—get back the life they feared they had lost.

Nexstim Plc publishes 2017 Annual Report

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announces the publication of its 2017 Annual Report. These documents are available on the “Investor Relations” section of the Company's website at www.nexstim.com.

The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement.

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

About Nexstim Plc

Nexstim is a neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBT® system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBT® system for this important indication during Q2 2018.

The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

Nexstim Plc Annual Report 2017

Nexstim Abp Årsredovisning 2017

Nexstim Oyj Vuosikertomus 2017